Refractory Kasabach-Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work

J Dermatol. 2015 Apr;42(4):401-4. doi: 10.1111/1346-8138.12797. Epub 2015 Feb 24.

Abstract

Kasabach-Merritt phenomenon (KMP) is a rare and life-threatening disease involving a vascular tumor combined with severe consumptive coagulopathy. We present for the first time a case of KMP with the vascular tumor involving two anatomical sites; the patient failed to respond to steroids and vincristine. Following sirolimus therapy at a dose of 0.8 mg/m(2) twice daily, the lesions shrank and the platelet count improved and remained normal 4 months after initial therapy. Current treatments for KMP are not particularly effective. Sirolimus at 0.8 mg/m(2) per dose, administrated twice daily, appears to be a safe and effective management option. It appears to be an interesting therapeutic option in refractory KMP, but the time to response is variable.

Keywords: Kasabach-Merritt phenomenon; case report; mini-review; sirolimus; treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Humans
  • Infant
  • Kasabach-Merritt Syndrome / blood
  • Kasabach-Merritt Syndrome / drug therapy*
  • Kasabach-Merritt Syndrome / pathology
  • Male
  • Platelet Count
  • Sirolimus / administration & dosage
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus